Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VRAYLAR vs ALBENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Schizophrenia,Acute treatment of manic or mixed episodes associated with bipolar I disorder,Depressive episodes associated with bipolar I disorder (bipolar depression)
FDA-approved: Hydatid disease (Echinococcus granulosus) and neurocysticercosis (Taenia solium).,Off-label: Ascariasis, trichuriasis, hookworm infections, enterobiasis, strongyloidiasis, cutaneous larva migrans, giardiasis, microsporidiosis, and other parasitic infestations.
1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
The terminal elimination half-life of cariprazine is 2-4 days, and for its active metabolites (desmethylcariprazine and didesmethylcariprazine) it is 1-3 weeks. This long half-life results in steady-state concentrations being reached after 3-4 weeks of daily dosing, contributing to prolonged clinical effects and a need for slow titration.
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Active metabolites include didesmethylcariprazine (DDCAR) and desmethylcariprazine (DCAR).
Primarily metabolized by hepatic microsomal enzymes, specifically to albendazole sulfoxide (active metabolite) via CYP3A4 and possibly other CYP isoforms. Further metabolized to albendazole sulfone (inactive) and other metabolites.
Cariprazine and its active metabolites are primarily eliminated via hepatic metabolism and subsequent biliary/fecal excretion. Approximately 20% of the dose is recovered in urine, mainly as inactive metabolites, while about 80% is recovered in feces, largely as unchanged cariprazine and its active metabolites.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Cariprazine is 91-97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Albendazole: ~70% bound to plasma proteins (mainly albumin). Albendazole sulfoxide: ~70% bound.
The apparent volume of distribution (Vd/F) is approximately 8.3 L/kg, indicating extensive tissue distribution and high lipophilicity.
Albendazole sulfoxide: 0.8-1.2 L/kg, indicating extensive tissue distribution including bile and CSF.
Absolute oral bioavailability is not determined; however, after oral administration, peak plasma concentrations occur within 3-6 hours. Food does not significantly affect the extent of absorption.
Oral: Poor bioavailability (~5-10%) of parent drug due to extensive first-pass metabolism; enhanced (up to 5-fold) with high-fat meal. Not administered parenterally.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1.5 mg daily; maximum 3 mg/day. Child-Pugh Class C: Not recommended.
Contraindicated in patients with known cirrhosis (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B), monitor liver function; dose adjustment not established.
Safety and efficacy not established in pediatric patients under 18 years; not recommended.
For children ≥2 years: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis. For children <2 years: not recommended.
Elderly patients may have lower clearance; use lowest effective dose (1.5 mg daily) and titrate slowly. Not approved for dementia-related psychosis due to increased mortality risk.
No specific dose adjustment recommended; use with caution due to potential hepatic and renal decline. Monitor for adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
NOT FDA APPROVED FOR ANY INDICATION IN THE UNITED STATES. (Note: This warning applies as Albendazole is not FDA-approved for use in the US; however, it is marketed elsewhere. In the US, it is available under an investigational protocol or as a compounded product.)
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse reactions in elderly patients with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Leukopenia, neutropenia, and agranulocytosis,Orthostatic hypotension and syncope,Falls,Seizures,Body temperature dysregulation,Dysphagia,Cognitive and motor impairment
Bone marrow suppression: Monitor blood counts regularly; risk of agranulocytosis, pancytopenia.,Hepatotoxicity: Elevation of liver enzymes; contraindicated in patients with hepatic disease or abnormal liver function tests.,Neurotoxicity: Risk of seizures, especially in neurocysticercosis due to inflammatory response to dying parasites.,Carcinogenicity: Long-term use associated with increased risk of tumors in animal studies.,Pregnancy: Category D (positive evidence of human fetal risk); avoid use in pregnant women or those likely to become pregnant.
Known hypersensitivity to cariprazine or any components of the formulation
Hypersensitivity to albendazole or benzimidazole compounds.,Pregnancy (Category D) and lactation.,Pre-existing hepatic disease or unexplained liver function test abnormalities.,Bone marrow depression or severe neutropenia.
No specific food restrictions. Vraylar can be taken with or without food. Grapefruit and grapefruit juice do not significantly interact with Vraylar. High-fat meals do not affect absorption.
Albendazole absorption is enhanced by fatty foods; a high-fat meal increases plasma concentration of the active metabolite albendazole sulfoxide by up to 5-fold. Avoid grapefruit juice as it may alter metabolism via CYP3A4 inhibition. Fatty meals are recommended to maximize efficacy.
First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following late third trimester exposure. Vraylar (cariprazine) is classified as Pregnancy Category C; no adequate human studies.
Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of congenital malformations when used during pregnancy, including craniofacial defects and limb abnormalities. Use is not recommended in women who are or may become pregnant.
Excretion into human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, discontinue drug or nursing, considering importance of drug to mother.
Albendazole is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.1. Due to potential adverse effects in nursing infants (e.g., bone marrow suppression, hepatic effects), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
No established dosing adjustments for pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure. Use lowest effective dose and monitor clinical response and tolerability. Clinical pharmacokinetic data not available; consider empiric dose adjustment based on tolerability.
No specific dosing adjustments for pregnancy are established. Use is contraindicated in pregnancy due to teratogenicity. If treatment is necessary, avoid during first trimester and use the lowest effective dose for the shortest duration under strict medical supervision. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may require therapeutic drug monitoring if available.
Vraylar (cariprazine) requires dose adjustment in moderate hepatic impairment (Child-Pugh B): maximum dose 3 mg/day. Avoid in severe hepatic impairment (Child-Pugh C). Titrate slowly to minimize akathisia risk. For acute mania, start at 1.5 mg/day on day 1, increase to 3 mg/day on day 2. For schizophrenia, start at 1.5 mg/day, may increase to 3 mg/day after 2 days, then further in 1.5 mg increments weekly. For bipolar depression, target dose is 1.5-3 mg/day; start at 1.5 mg/day, increase to 3 mg/day after 2 days if needed. Monitor for extrapyramidal symptoms, especially akathisia which is dose-dependent. Renal impairment: no dose adjustment needed. CYP3A4 inducers (e.g., rifampin) decrease exposure; may need dose increase. CYP3A4 inhibitors (e.g., ketoconazole) increase exposure; reduce dose.
Albendazole is a broad-spectrum anthelmintic effective against intestinal and tissue nematodes, cestodes, and some protozoa. It is poorly absorbed orally; co-administration with a fatty meal significantly increases bioavailability (up to 5-fold). Monitor liver function tests periodically due to risk of hepatotoxicity. Contraindicated in pregnancy (category C) and in patients with known hypersensitivity. For neurocysticercosis, concomitant corticosteroids and antiepileptics are often required to manage inflammatory reactions. May cause bone marrow suppression; obtain CBC at baseline and periodically. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Take Vraylar once daily with or without food. Swallow capsules whole; do not crush or chew.,Do not abruptly stop taking Vraylar without talking to your doctor; sudden discontinuation may cause withdrawal symptoms such as nausea, vomiting, or trouble sleeping.,Avoid alcohol and illicit drugs while taking Vraylar, as they can worsen side effects like dizziness or drowsiness.,You may experience restlessness or an urge to move (akathisia), especially during dose increases; tell your doctor if this occurs.,Vraylar may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how the medication affects you.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double up.,Contact your doctor immediately if you experience uncontrolled muscle movements, especially of the face or tongue, or signs of neuroleptic malignant syndrome (fever, muscle rigidity, confusion).,Store at room temperature 20-25°C (68-77°F), away from moisture and heat.
Take with a high-fat meal to increase absorption.,Complete the full course of therapy even if symptoms improve.,Use effective contraception during treatment and for at least 1 month after the last dose.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain.,May cause dizziness; avoid driving or operating machinery if affected.,Notify your healthcare provider if you experience persistent sore throat, fever, or unusual bleeding/bruising.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VRAYLAR vs ALBENZA, answered by our medical review team.
VRAYLAR is a Atypical Antipsychotic that works by Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.. ALBENZA is a Anthelmintic that works by Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VRAYLAR and ALBENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VRAYLAR is: 1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.. The standard adult dose of ALBENZA is: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VRAYLAR and ALBENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VRAYLAR is classified as Category C. First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following l. ALBENZA is classified as Category C. Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.